ARTICLE | Company News
Orexo sales and marketing update
September 16, 2013 7:00 AM UTC
Orexo launched Zubsolv buprenorphine/naloxone in the U.S. to treat opioid dependence. FDA approved the sublingual tablet formulation of buprenorphine and naloxone in July. The wholesale acquisition ...